[Update on the current diagnosis and therapy of peripheral arterial occlusive disease]. / Update über die aktuelle Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK).

Update on the current diagnosis and therapy of peripheral arterial occlusive disease Abstract. The prevalence of peripheral arterial disease (PAOD) increases with age and overall due to demographic trends. The symptoms severely reduce the quality of life. The 5-year mortality rate is even twice as high as in patients without PAOD. It is also higher than those of patients with coronary or cerebrovascular disease. Therefore it is important to identify those high-risk patients. Screening and diagnosing - not exclusion of the disease - is possible through clinical observation (pulse palpation) or with the help of simple equipment (messurement of the Ankle-Brachial-Index (ABI)) by any general practitoner. Further examination including imageing is done stepwise and with the goal of choice of best treatment. The most important part in all stages of PAOD is the treatment of cardiovascular risk factors. After lifestyle modification (smoking cessation, weight reduction and regular physical activity) several drug-assisted therapies should be considered e. g. to lower LDL-cholesterol levels < 1.8 mmol / L. and blood pressure < 130 / 80 mmHg combined with antiplatelet or anticoagulant agents.The first-line active treatment of claudicant patients is walking exercise. In patients with insufficient improvement in walking exercise and in patients with critical limb ischaemia, revasculatization is indicated. In recent years, the endovascular therapy possibilities have expended significantly through increasing experience and technological innovations also for occlusions in iliac arteries and long occlusions (> 25 cm) in the superficial femoral and popliteal artery, especially for patients with high perioperative risk. Some indications for primarly surgical therapy remain, for example long occlusions in femoro-popliteal arteries in patients with a low perioperative risk and stenosis / occlusions in the femoral bifurcation. The decision making for the optimal therapy for the patient should be taylored individually and interdisciplinary.

Brucellosis and thrombosis of the inferior vena cava.

We describe the case of a 23-year old woman with a newly diagnosed thrombosis of the inferior vena cava associated with a Brucella melitensis infection. We suggest possible mechanisms leading to brucellosis-associated venous thrombosis and review 14 previously reported cases.
.

Pelvic congestion syndrome and left renal compression syndrome - clinical features and therapeutic approaches.

Knowledge of the anatomy of the pelvic, gonadal and renal veins is important to understand pelvic congestion syndrome (PCS) and left renal vein compression syndrome (LRCS), which is also known as the nutcracker syndrome. LRCS is related to PCS and to the presence of vulvar, vaginal and pudendal varicose veins. The diagnosis of the two syndromes is difficult, and usually achieved with CT- or phlebography. The gold standard is the intravenous pressure measurement using conventional phlebography. The definition of PCS is described as pelvic pain, aggravated in the standing position and lasting for more than 6 months. Pain in the left flank and microhaematuria is seen in patients with LRCS. Women with multiple pregnancies are at increased risk of developing varicose vein recurrences with pelvic drainage and ovarian vein reflux after crossectomy and stripping of the great saphenous vein. The therapeutic options are: conservative treatment (medroxyprogesteron) or interventional (coiling of the ovarian vein) or operative treatment (clipping of the ovarian vein). Controlled prospective trials are needed to find the best treatment.

Impact of compression stockings on calf-vein diameters and on quality of life parameters in subjects with painful legs.

BACKGROUND: Calf vein diameters during compression with two different stocking brands are assessed as well as quality of life. PATIENTS AND METHODS: 60 subjects (53 female) with painful legs were randomized to either wearing the Venotrain micro® (VM) or the Venotrain ulcertec® (VU) compression stocking for 2 weeks. All calf - veins were assessed in cross - sectional plane by Duplexsonography native and through the compression stockings. The diameters of 2 gastrocnemius muscle - veins (GV), the short saphenous vein (SSV) and the posterior tibial vein (PTV) were compared intra - individually, with and without compression. RESULTS: Mean diameters (± SD) decreased significantly under compression (p < 0.0001) in the standing position: in the antero-posterior (ap) plane of the GV by 6.5 (± 16.6) % under VU and 8.2 (± 16.5) % under VM, in the SSV 9.7 (± 15.8) % under VU and 5.7 (± 19.2) % under VM. No significant change (p = 0.48) was seen in the PTV. In the prone position the relative ap - diameter changes in the medial GV were significantly smaller for the VM (37.5 ± 51.0 %) compared to the VU compression stocking (52.4 ± 51.8 %) (p = 0.016). The quality of life assessment scores improved significantly for the VU - and the VM - compression stocking. Venous diameters did not correlate with quality of life scores. CONCLUSIONS: Intra - individually tested the calf muscle vein diameters decrease under compression, more pronounced in the prone than in the standing position. In the ankle area the PTV does not decrease in standing subjects. Quality of life assessed increases for both compression stockings.

Compression to prevent the postthrombotic syndrome.

Summary We give an overview on the current literature concerning compression in the prevention of postthrombotic syndrome, including our own investigations of the hemodynamic changes over time in female and male patients. We also describe the evaluation of a combined reflux-occlusion score to predict occurrence of new pigmentation (C4).

Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial.

OBJECTIVE: Compression stockings are widely applied after acute proximal deep vein thrombosis, but their efficacy in preventing the post-thrombotic syndrome remains controversial. This study assessed the effect of prolonged compression therapy after a standard treatment of 6 months after acute deep vein thrombosis. METHODS: Of 900 patients screened, we randomly allocated 169 patients with a first or recurrent proximal deep vein thrombosis after receiving 6 months of standard treatment to wear compression stockings or not. Primary efficacy analysis was performed on the end point of emerging skin changes (C4-C6 according to the CEAP classification). Secondary analysis was done on symptoms associated with post-thrombotic syndrome. All analyses were done according to the intention-to-treat principle. RESULTS: The primary end point occurred in 11 patients (13.1%) in the treatment group compared with 17 (20.0%) in the control group (hazard ratio [HR], 0.60; 95% confidence interval [CI], 0.28-1.28; P = .19). Mean follow-up was 3.2 years and 2.9 years, respectively. Five additional patients in the control group required compression therapy owing to post-thrombotic signs and symptoms not included in the primary end point. No venous ulceration was observed in either group. Within subgroup analyses of the primary end point, we observed a large sex-specific difference between women (HR, 0.11; 95% CI, 0.02-0.91) and men (HR, 1.07; 95% CI, 0.42-2.73). Symptom relief was significant in favor of compression treatment during the first year but not thereafter. CONCLUSION: Prolonged compression therapy after proximal deep vein thrombosis significantly reduces symptoms and may prevent post-thrombotic skin changes. Whether these findings translate to the prevention of advanced disease states with ulcerations remains unclear.

Acute occlusive large vessel disease leading to fatal stroke in a patient with systemic lupus erythematosus: arteritis or atherosclerosis?

A woman with a history of systemic lupus erythematosus presented with extensive bilateral strokes due to acute inflammatory, occlusive large vessel disease affecting several aortic branches including the carotid, subclavian, renal, and iliac arteries. We quantitatively characterized the arterial inflammation in this patient and compared it with the inflammatory infiltrates from 22 patients with conventional atherosclerosis. Profound histomorphologic differences from conventional atherosclerosis (predominance of CD8-positive lymphocytes, relative absence of macrophages, no ectopic neovascularization, no signs of plaque hemorrhage, concentric instead of eccentrical stenosis) suggest that this patient's accelerated arteriopathy was precipitated by pathogenic events other than conventional atherosclerosis.

Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes.

The atherogenic lipoprotein phenotype is characterized by an increase in plasma triglycerides, a decrease in high-density lipoprotein (HDL), and the prevalence of small, dense low-density lipoprotein (LDL) particles. The present study investigated the clinical significance of LDL size and subclasses as markers of atherosclerosis in diabetes type 2. Thirty-eight patients with type 2 diabetes, total cholesterol of less than 6.5 mmol/L, and hemoglobin A1c (HbA1c) of less than 9% were studied. Median age was 61 years, mean (+/-SD) body mass index 29 +/- 4.3 kg/m2 , and mean HbA1c 7.1 +/- 0.9 %. Laboratory parameters included plasma lipids and lipoproteins, lipoprotein (a), apolipoprotein (apo) A-I, apo B-100, apo C-III, and high-sensitivity C-reactive protein. Low-density lipoprotein size and subclasses were measured by gradient gel electrophoresis and carotideal intima media thickness (IMT) by duplex ultrasound. By factor analysis, 10 out of 21 risk parameters were selected: age, body mass index, systolic blood pressure, smoking (in pack-years), HbA1c, high-sensitivity C-reactive protein, lipoprotein (a), LDL cholesterol, HDL cholesterol, and LDL particle size. Multivariate analysis of variance of these 10 risk parameters identified LDL particle size as the best risk predictor for the presence of coronary heart disease (P = .002). Smaller LDL particle size was associated with an increase in IMT (P = .03; cut-off >1 mm). Within the different lipid parameters (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apo B, apo A-I, apo C-III, LDL particle size), LDL particle size was most strongly associated with the presence of coronary heart disease (P = .002) and IMT (P = .03). It is concluded that LDL size is the strongest marker for clinically apparent as well as non-apparent atherosclerosis in diabetes type 2.

Great saphenous vein stripping with liberal use of subfascial endoscopic perforator vein surgery (SEPS).

This study is based on a unique registry of 632 patients who underwent great saphenous vein (GSV) stripping and liberal use of subfascial endoscopic perforator vein surgery (SEPS) for minimal to severe lower limb venous insufficiency. Clinical examinations and color-coded duplex scanning were performed on a randomly selected, manageable sample of 170 limbs to assess the affect of early SEPS on junctional (saphenofemoral [SFJ] and/or saphenopopliteal [SPJ]) and perforator vein (PV) insufficiencies and superficial varicosities at a median of 6.5 years. PV incompetence was present in 68 legs (40%), as the sole transfascial insufficiency in 28 limbs and combined with SFJ or SPJ incompetence in 40 limbs. Junction incompetence alone characterized an additional 38 limbs, bringing the total transfascial insufficiency prevalence to 62%. Superficial varicosities affected 46% of limbs. Overall CEAP clinical class was unimproved beyond preoperative values. PV incompetence was associated with higher CEAP and clinical venous severity scores than were junctional insufficiencies alone. We concluded that PV incompetence alone or combined with junctional insufficiency is associated with increased symptoms and disease progression. The prevalence of SFJ, SPJ, and PV incompetence (62%) and recurrent varicosities (46%) suggests that early use of SEPS does not prevent disease progression and offers no benefit over GSV stripping in the absence of deep vein insufficiency or threatened ulceration.

Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease.

BACKGROUND: Vascular endothelial cells form the interface between recipient tissues and circulating alloreactive donor T cells after allogeneic stem cell transplantation. Vascular injury has been seen in patients with acute graft versus host disease (GVHD) in the skin. We aimed to see whether vascular injury mediated by cytotoxic T lymphocytes and microvessel loss arises in patients with chronic GVHD. METHODS: We investigated eight patients with acute GVHD and ten with chronic GVHD for signs of endothelial injury and microvessel loss by measurement of von Willebrand factor (vWF) in plasma and blood vessel density in biopsy samples taken from lesional skin. Controls consisted of nine patients without GVHD who survived for longer than 100 days and nine healthy people. Inflammation and endothelial injury were assessed in selected samples by immunostaining for CD8 T cells, activated cytotoxic T lymphocytes, and vascular endothelial cells. FINDINGS: We identified more extensive loss of microvessels in the skin of patients with GVHD (median 66 capillaries/mm(2); IQR 16-98) than of healthy controls (205 capillaries/mm(2); 157-226; p=0.005). Patients with GVHD had higher concentrations of vWF (238%; 168-288) than did those without GVHD (102%; 88-118; p=0.0005). Perivascular CD8 T cell infiltrates in skin correlated with vWF plasma concentrations in patients with GVHD (p=0.01), and activated cytotoxic T lymphocytes and endothelial injury were present in these same samples. INTERPRETATION: Host endothelial cells are a target of alloreactive donor cytotoxic T lymphocytes. Substantial blood vessel loss may lead to impaired blood perfusion and tissue fibrosis, the hallmark lesion of chronic GVHD.

Osteomyelitis of the cervical spine: a potentially dramatic disease.

Osteomyelitis of the cervical spine is a rare disease, representing only 3% to 6% of all cases of vertebral osteomyelitis. In contrast with other locations of spinal infections, osteomyelitis of the cervical spine can be a much more dramatic and rapidly deteriorating process, leading to early neurologic deficit. Thus, the disease must be diagnosed quickly and appropriate therapy initiated as soon as possible. The clinical course, therapy, and outcome of 15 patients treated for osteomyelitis of the cervical spine are presented. Nine of 15 patients presented with a neurologic deficit at the time of diagnosis. Surgical treatment consisted of radical debridement of the infected bone and either immediate bone grafting and stabilization as a one-step procedure or interval antibiotic treatment before bone grafting and surgical stabilization as a second procedure. A favorable outcome was achieved by early and aggressive surgical intervention, including complete resolution of neurologic deficits in more than 50% of the patients and complete bony fusion in all but one patient. The authors prefer additional posterior rather than anterior stabilization alone to perform fusion over a shorter distance involving only the infected segments.